NCT06202235 Multifrequency MRE in Evaluation of Chronic Kidney Diseases
| NCT ID | NCT06202235 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Shengjing Hospital |
| Condition | Chronic Kidney Disease (CKD) |
| Study Type | OBSERVATIONAL |
| Enrollment | 200 participants |
| Start Date | 2022-10-10 |
| Primary Completion | 2027-06-08 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 200 participants in total. It began in 2022-10-10 with a primary completion date of 2027-06-08.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Chronic Kidney Disease (CKD) is a major public health issue, leading to high mortality and the necessity for renal replacement therapy. Kidney fibrosis, resulting from chronic damage to kidney tissue, significantly determines CKD outcomes. Kidney biopsy, the gold standard for assessing fibrosis, is invasive and limited in its ability to reflect the heterogeneous nature of fibrosis. Consequently, there is growing interest in noninvasive methods, particularly Magnetic Resonance Elastography (MRE). MRE, which evaluates tissue stiffness, has shown potential for assessing kidney fibrosis. This study aims to use multifrequency MRE to assess renal fibrosis, focusing particularly on the early stages of CKD, to enhance understanding of its progression and relationship to clinical outcomes.
Eligibility Criteria
Inclusion Criteria: (1) adults with CKD defined according to the 2024 KDIGO guidelines, with either elevated SCr or abnormal proteinuria ; and (2) renal MRI was performed within 7 days of the renal biopsy. Exclusion criteria: (1) genitourinary malignancy, polycystic kidney disease, renal transplantation, or acute renal failure; (2) contraindications for MRI examination; (3) poor image quality; (4) kidney deformity or severe hydronephrosis on MRI; and (5) poorly defined corticomedullary demarcation.
Contact & Investigator
yu shi, MD
PRINCIPAL INVESTIGATOR
Shengjing Hospital
Frequently Asked Questions
Who can join the NCT06202235 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 65 Years, studying Chronic Kidney Disease (CKD). Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06202235 currently recruiting?
Yes, NCT06202235 is actively recruiting participants. Contact the research team at 18940259980@163.com for enrollment information.
Where is the NCT06202235 trial being conducted?
This trial is being conducted at Shenyang, China.
Who is sponsoring the NCT06202235 clinical trial?
NCT06202235 is sponsored by Shengjing Hospital. The principal investigator is yu shi, MD at Shengjing Hospital. The trial plans to enroll 200 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.